Company research
Indaptus Therapeutics, Inc.
CIK 1857044Updated Oct 23, 2026
SecurityINDP · NASDAQ · equity
Name history
Intec Parent Inc. · through Aug 3, 2021
INDP price & chart
Loading TradingView…
NASDAQ:INDP on TradingView ↗In the news
Indaptus Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update ↗
Recent filings
10-Q filing
Other Events
Items 8.01
S-8 filing
Entry into a Material Definitive Agreement
Items 1.01, 9.01
Entry into a Material Definitive Agreement · Unregistered Sales of Equity Securities
Items 1.01, 3.02, 9.01
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 6,840,052Source | 8,239,806Source | 11,987,956Source | 6,839,207Source | 8,121,835Source | — | 5,411,622Source | 10,948,515Source | 9,310,168Source | 7,338,756Source | 14,923,878Source | 28,063,806Source |
| Property, Plant and Equipment, NetUSD | — | — | — | — | — | — | — | — | — | — | 735Source | 2,019Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 5,825,639Source | 7,380,686Source | 7,553,820Source | 6,157,701Source | 7,301,751Source | 1,497,635Source | 3,891,021Source | 9,741,638Source | 8,507,628Source | 5,786,753Source | 13,362,053Source | 9,626,800Source |
| Assets, CurrentUSD | 6,438,993Source | 7,629,423Source | — | 6,413,058Source | 7,488,477Source | 2,180,856Source | 4,960,931Source | 10,292,669Source | 9,310,168Source | 6,618,330Source | 13,995,209Source | 27,244,242Source |
| Prepaid Expense and Other Assets, CurrentUSD | 613,354Source | 248,737Source | 434,136Source | 255,357Source | 186,726Source | 683,221Source | 1,069,910Source | 551,031Source | 802,540Source | 831,577Source | 633,156Source | 811,433Source |
| Operating Lease, Right-of-Use AssetUSD | 8,487Source | 105,655Source | — | 33,577Source | 128,630Source | — | 58,119Source | 151,118Source | — | 82,175Source | 173,206Source | 79,294Source |
| Other Assets, NoncurrentUSD | 392,572Source | 504,728Source | — | 392,572Source | 504,728Source | — | 392,572Source | 504,728Source | — | 638,251Source | 754,728Source | 738,251Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | — | 2,236,480Source | 615,426Source | — | 1,955,627Source | — | — | 1,587,956Source | — | 3,393,881Source | 2,847,380Source | 3,433,341Source |
| Stockholders’ equity: | ||||||||||||
| Preferred Stock, Value, IssuedUSD | — | — | — | — | — | — | — | — | 10,000Source | — | — | — |
| Common Stock, Value, IssuedUSD | 16,420Source | 101,969Source | 1,332,424Source | 6,050Source | 85,531Source | 1,132,424Source | 160,344Source | 85,389Source | 21,674Source | 120,139Source | 84,011Source | 84,011Source |
| Additional Paid in CapitalUSD | 77,764,956Source | 62,209,493Source | 95,664,138Source | 68,521,126Source | 59,319,777Source | 83,944,602Source | 67,611,000Source | 58,499,003Source | 84,408,018Source | 64,263,919Source | 57,409,643Source | 54,443,705Source |
| Retained Earnings (Accumulated Deficit)USD | -73,175,649Source | -56,308,136Source | -85,624,032Source | -70,200,532Source | -53,239,100Source | -83,829,169Source | -64,971,613Source | -49,223,833Source | -81,288,099Source | -60,439,183Source | -45,417,156Source | -29,993,685Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | — | — | — | — | — | — | — | — | — | — | — | 96,434Source |
| Stockholders' Equity Attributable to ParentUSD | 4,605,727Source | 6,003,326Source | 11,372,530Source | -1,673,356Source | 6,166,208Source | 1,247,857Source | 2,799,731Source | 9,360,559Source | 3,151,593Source | 3,944,875Source | 12,076,498Source | 24,630,465Source |
| Liabilities and EquityUSD | 6,840,052Source | 8,239,806Source | 11,987,956Source | 6,839,207Source | 8,121,835Source | 2,180,856Source | 5,411,622Source | 10,948,515Source | 9,310,168Source | 7,338,756Source | 14,923,878Source | 28,063,806Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 2,234,325Source | 2,232,473Source | — | 8,512,563Source | 1,928,048Source | 932,999Source | 2,611,891Source | 1,537,292Source | 6,158,575Source | 3,393,881Source | 2,774,032Source | 3,433,341Source |
| Operating Lease, Liability, CurrentUSD | 8,686Source | 103,982Source | — | 34,373Source | 103,223Source | — | 59,512Source | 102,464Source | — | 84,164Source | 101,705Source | 80,494Source |
| Accounts Payable, CurrentUSD | 707,420Source | 555,949Source | 508,877Source | 618,515Source | 416,555Source | 557,367Source | 1,311,095Source | 405,457Source | 544,057Source | 870,229Source | 806,004Source | 1,378,316Source |
| Operating Lease, Liability, NoncurrentUSD | — | 4,007Source | — | — | 27,579Source | — | — | 50,664Source | — | — | 73,348Source | — |
| Short-term Investments | — | — | —Source | — | — | — | — | — | — | — | — | — |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | 150,614Source | 444,184Source | — | — | 227,180Source | 240,891Source | 1,358,082Source | 2,305,849Source | 2,965,938Source | 2,957,249Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -7,009,993Source | -5,047,127Source | -14,823,256Source | -12,323,188Source | -13,405,315Source | -13,078,347Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | — | — | — | — | 17,140,568Source | -16,427,018Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | — | 3,151,395Source | 17,544,131Source | 4,747,888Source | — | — |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | — | — | — | 1,600Source | 1,600Source | 2,400Source |
| Additional Financial Items | ||||||||||||
| DepreciationUSD | — | — | — | — | — | — | — | — | — | 735Source | 1,284Source | 1,781Source |
| General and Administrative ExpenseUSD | — | — | 1,130,764Source | 1,676,020Source | 1,445,739Source | 2,289,649Source | 1,668,454Source | 1,761,719Source | 10,492,554Source | 8,114,654Source | 8,756,767Source | 8,586,249Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 1,716Source | 1,700Source | 2,450Source | 30Source |
| Marketable Securities, Unrealized Gain (Loss)USD | — | — | — | — | — | — | — | — | — | — | — | 96,434Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -2,975,117Source | -3,069,036Source | -1,794,863Source | -5,228,919Source | -2,541,070Source | -4,532,430Source | -20,848,916Source | -15,022,027Source | -15,423,471Source | -14,322,798Source |
| Nonoperating Income (Expense)USD | — | — | — | 73,021Source | — | — | — | 40,129Source | — | 343,724Source | 955,003Source | 588,108Source |
| Operating ExpensesUSD | — | — | 2,648,487Source | 3,142,057Source | 1,808,866Source | 4,456,763Source | 2,159,588Source | 4,572,559Source | 19,833,513Source | 15,365,751Source | 16,378,474Source | 14,910,906Source |
| Other Operating Income (Expense), NetUSD | — | — | 39,088Source | 73,021Source | — | 15,547Source | — | 40,129Source | 138,018Source | 343,724Source | — | — |
| Proceeds from Issuance of Common StockUSD | — | — | — | 2,500,000Source | — | — | — | 3,482,650Source | 6,396,888Source | 5,510,591Source | — | — |
| Other Nonoperating Income (Expense) | — | — | — | — | —Source | —Source | —Source | —Source | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income (Loss)USD | — | — | -2,648,487Source | -3,142,057Source | -1,808,866Source | -4,456,763Source | -2,159,588Source | -4,572,559Source | -19,833,513Source | -15,365,751Source | -16,378,474Source | -14,910,906Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | — | — | — | — | — | — | -20,847,194Source | — | — | — |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 1,716Source | 1,700Source | 2,450Source | 30Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -2,975,117Source | -3,069,036Source | -1,794,863Source | -5,228,919Source | -2,541,070Source | -4,532,430Source | -20,848,916Source | -15,022,027Source | -15,423,471Source | -14,322,798Source |
| Earnings Per Share, BasicUSD per share | — | — | -2.98Source | -9.04Source | -0.02Source | -9.09Source | -0.23Source | -9.11Source | -21.58Source | -1.61Source | -1.83Source | -1.73Source |
| Earnings Per Share, DilutedUSD per share | — | — | -2.98Source | -9.04Source | -0.02Source | -9.09Source | -0.23Source | -9.11Source | -21.58Source | -1.61Source | -1.83Source | — |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 997,038Source | 339,659Source | 116,131,213Source | 574,923Source | 10,956,650Source | 497,794Source | 966,124Source | 9,355,710Source | 8,401,047Source | 8,262,119Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 997,038Source | 339,659Source | 116,131,213Source | 574,923Source | 10,956,650Source | 497,794Source | 966,124Source | 9,355,710Source | 8,401,047Source | — |
| Additional Financial Items | ||||||||||||
| Current Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 1,716Source | — | — | — |
| General and Administrative ExpenseUSD | — | — | 1,130,764Source | 1,676,020Source | 1,445,739Source | 2,289,649Source | 1,668,454Source | 1,761,719Source | 10,492,554Source | 8,114,654Source | 8,756,767Source | 8,586,249Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | -21,447,994Source | — | — | — |
| Nonoperating Income (Expense)USD | — | — | — | 73,021Source | — | — | — | 40,129Source | — | 343,724Source | 955,003Source | 588,108Source |
| Operating ExpensesUSD | — | — | 2,648,487Source | 3,142,057Source | 1,808,866Source | 4,456,763Source | 2,159,588Source | 4,572,559Source | 19,833,513Source | 15,365,751Source | 16,378,474Source | 14,910,906Source |
| Other Operating Income (Expense), NetUSD | — | — | 39,088Source | 73,021Source | — | 15,547Source | — | 40,129Source | 138,018Source | 343,724Source | — | — |
| Research and Development ExpenseUSD | — | — | 1,517,723Source | 1,466,037Source | 363,127Source | 2,167,114Source | 491,134Source | 2,810,840Source | 9,340,959Source | 7,251,097Source | 7,621,707Source | 6,324,657Source |
| Other Nonoperating Income (Expense) | — | — | — | — | —Source | —Source | —Source | —Source | — | — | — | — |
Offerings
Registration 333-298388
Registration 333-297088
Filing attachments
ex107.htm · S-8 · 2026-10-05
Calculation of Filing Fee Tables S-8 Indaptus Therapeutics, Inc. ──────────────────────────────────── Table 1: Newly Registered Securities ──────────────────────────────────────── Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee ────────────────────────────────────────…
Read attachment ↗ex107.htm · S-3 · 2026-08-17
Calculation of Filing Fee Tables S-3 Indaptus Therapeutics, Inc. ──────────────────────────────────── Table 1: Newly Registered and Carry Forward Securities ☐Not Applicable ─────────────────────────────────────────────────────────────────────────────── Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Off…
Read attachment ↗ex99-1.htm · 8-K · 2026-08-13
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Indaptus Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update NEW YORK (August 13, 2026) - Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a biotechnology company dedicated to immunotherapy research, today announced financial results for the second quarter and six months ended June 30, 2026, and provided a corporate update. Junyi Dai, Indaptus Therapeutics’ Chief Executive Officer and C…
Read attachment ↗indaptustherapeutics_ex99-1.htm · SCHEDULE 13D/A · 2026-06-26
Exhibit 99.1 EXHIBIT 99.1 - JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a Statement on Schedule 13D (including any and all amendments thereto) with respect to the common stock, par value $0.01 per share, of Indaptus Therapeutics, Inc., a Delaware corporation, and further agree that this Joint Filing Agreement shall be included as an Exhibit to such joint fil…
Read attachment ↗ex107.htm · S-3 · 2026-06-26
Calculation of Filing Fee Tables S-3 Indaptus Therapeutics, Inc. ──────────────────────────────────── Table 1: Newly Registered and Carry Forward Securities ☐Not Applicable ─────────────────────────────────────────────────────────────────────────────── Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Off…
Read attachment ↗ex99-1.htm · 8-K · 2026-05-15
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Indaptus Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update NEW YORK (May 15, 2026) - Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a clinical-stage biotechnology company, today announced financial results for the first quarter ended March 31, 2026, and provided a strategic corporate update. Junyi Dai, Indaptus Therapeutics’ Chief Executive Officer and Chairman of the Board, commente…
Read attachment ↗